Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$79.24 USD

79.24
4,047,114

-0.85 (-1.06%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $79.20 -0.04 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why Is Penumbra (PEN) Up 20% Since Last Earnings Report?

by Zacks Equity Research

Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Hologic (HOLX) Down 3.4% Since Last Earnings Report?

by Zacks Equity Research

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Edwards Lifesciences (EW) Up 19.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

TFX or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

TFX vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

Should You Hold Edward Lifesciences (EW) in Your Portfolio Now?

by Zacks Equity Research

Edward Lifesciences' (EW) promising TAVR business and the Critical Care divestment move bode well in the long term.

Zacks Equity Research

TFX or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

TFX vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

Edwards Lifesciences (EW) Reliance on International Sales: What Investors Need to Know

by Zacks Equity Research

Evaluate Edwards Lifesciences' (EW) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Zacks Equity Research

Edwards Lifesciences (EW) Q2 Earnings Meet Mark, Margins Crash

by Zacks Equity Research

Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.

Zacks Equity Research

Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Edwards Lifesciences (EW) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Edwards Lifesciences (EW) Q2 Earnings Match Estimates

by Zacks Equity Research

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 16.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences

by Zacks Equity Research

Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.

Urmimala Biswas headshot

Can These 4 MedTech Stocks Hit Targets This Earnings Season?

by Urmimala Biswas

Here is a sneak peek into how four MedTech bigshots, BSX, TMO, ALGN and EW, are expected to fare in their second-quarter results, slated to be released tomorrow.

Zacks Equity Research

Earnings Preview: Integra LifeSciences (IART) Q2 Earnings Expected to Decline

by Zacks Equity Research

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions

by Zacks Equity Research

Edwards Lifesciences (EW) exercises the option to acquire Innovalve Bio-Medical Ltd., strengthening its TMVR technology portfolio and addressing unmet needs in structural heart disease.

Zacks Equity Research

Edwards Lifesciences (EW) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?

by Zacks Equity Research

Edwards Lifesciences' (EW) TMTT segment's PASCAL platform is likely to have maintained strong growth momentum in the second quarter globally, backed by its portfolio of differentiated therapies.

Zacks Equity Research

Can Elevance Health (ELV) Beat Q2 Earnings on Lower Expenses?

by Zacks Equity Research

Elevance Health's (ELV) second-quarter results are likely to be aided by improved product revenues, commercial fee-based membership growth, and lower expenses.

Zacks Equity Research

HOLX or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

Universal Health (UHS) Gains 28% in a Year: What Lies Ahead?

by Zacks Equity Research

Universal Health (UHS) remains well-poised for growth on the back of growing patient volumes, acquisitions and a commendable financial position.

Zacks Equity Research

HOLX vs. EW: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

BD (BDX) Inks Buyout Deal to Expand Smart Connected Care Suite

by Zacks Equity Research

BD's (BDX) latest agreement is likely to unlock new future value-creation opportunities and expand its portfolio of smart connected care solutions.

Zacks Equity Research

Why Is Idexx (IDXX) Up 5% Since Last Earnings Report?

by Zacks Equity Research

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

HOLX or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Retain Edward Lifesciences (EW) for Now

by Zacks Equity Research

Investors are optimistic about Edward Lifesciences (EW), led by the strong performance of its SAPIEN 3 Ultra RESILIA platform and strong solvency.